8-K: National Research Corporation Announces Executive Compensation Changes Following CEO Appointment

National Research Corporation adjusts executive compensation packages, including stock grants and bonuses, following the appointment of Trent Green as CEO.

Summary

• National Research Corporation's board of directors appointed Trent Green as CEO, effective June 1, 2025.
• Following this appointment, the Compensation and Talent Committee reevaluated the compensation packages of executive officers, excluding Mr. Green and current CEO Michael D. Hays.
• On April 3, 2025, a new compensation program was approved for Chief Operating Officer Helen L. Hrdy, including a grant of 100,000 shares of common stock issued on April 7, 2025, subject to certain restrictions.
• Ms. Hrdy will also receive a cash bonus equal to 66 2/3% of the value of the shares.
• In the event of termination without cause or resignation with good reason after the third anniversary of the grant date, Ms. Hrdy will be entitled to one year of continued payment of her then-current annual base salary.
• Ms. Hrdy's previous severance agreement and participation in the 2024 long-term cash incentive plan were terminated, and her unvested performance-based option to purchase 100,000 shares granted in January 2024 was forfeited.
• Ms. Hrdy's annualized base salary remains at $400,000.
• Similar compensation changes were made for Chief Corporate Development Officer Andrew Monnich.
• The compensation of current CEO Michael D. Hays was not changed.

Sentiment

Score: 7

Explanation: The announcement is generally positive as it outlines efforts to align executive compensation with shareholder interests and retain key personnel. The sentiment is slightly tempered by the forfeiture of previous stock options.

Positives

• The new compensation program aims to align the interests of executive officers with those of the shareholders through stock ownership.
• The changes provide retention incentives for key executives like Helen Hrdy and Andrew Monnich.

Negatives

• Helen Hrdy forfeited her unvested performance-based option to purchase 100,000 shares of the company's common stock granted in January 2024.

Risks

• The company has the option to repurchase the shares granted to Ms. Hrdy for $1.00 if she is terminated for cause or resigns without good reason prior to the third anniversary of the grant date, which could be seen as a risk for the executive.
• The transfer restrictions on the shares could limit Ms. Hrdy's flexibility in managing her personal finances.

Future Outlook

The company is implementing a new strategic plan associated with the appointment of Trent Green as CEO, and the executive compensation packages are being aligned with shareholders' interests.

Management Comments

• The Compensation and Talent Committee desired to align the compensation of such executive officers with our shareholders interests and perspectives through stock ownership.

Industry Context

Executive compensation adjustments are common following the appointment of a new CEO to align management incentives with the company's strategic goals.

Comparison to Industry Standards

• Stock grants and bonuses are typical components of executive compensation packages in publicly traded companies.
• Companies like Cerner (now Oracle Health) and Allscripts Healthcare Solutions, which operate in related healthcare technology sectors, also use stock-based compensation to incentivize executives.
• The specific terms of the stock grants, such as vesting schedules and transfer restrictions, are generally aligned with industry best practices to ensure retention and performance.

Management Changes

Stakeholder Impact

• Shareholders may view the alignment of executive compensation with stock ownership as a positive step.
• Employees, particularly Helen Hrdy and Andrew Monnich, are directly impacted by the compensation changes.
• The changes could influence the company's performance and, consequently, its relationships with customers and suppliers.

Key Dates

Keywords

executive compensation, CEO appointment, stock grant, National Research Corporation, Trent Green, Helen Hrdy, Andrew Monnich